Sebastian BioPharma
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Oncology
Sebastian BioPharma is a preclinical oncology company developing a next-generation Antibody–Oligonucleotide Conjugate (AOC) platform designed to overcome immunotherapy resistance in solid tumors. Our proprietary dual-siRNA technology enables simultaneous modulation of multiple intracellular pathways from a single, tissue-targeted antibody, addressing the biological complexity that limits current single-target therapies. Our lead program, SBP-001, focuses on immunotherapy-resistant colorectal cancer, where ~85% of patients do not respond to current treatments. We have demonstrated dual-target activity with in vitro and in vivo validation and are advancing toward drug candidate nomination. Founded by pioneers in RNA therapeutics and tumor immunology, Sebastian BioPharma is positioned at the intersection of ADCs, RNA therapeutics, and immuno-oncology to unlock programmable, multi-pathway control of disease.
Company HQ City:
Beverly
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
BP-001 is our lead program, a first-in-class dual-siRNA Antibody–Oligonucleotide Conjugate (AOC) designed to overcome immunotherapy resistance in solid tumors. It targets colorectal cancer by simultaneously addressing tumor invisibility and immune exclusion through coordinated modulation of two intracellular pathways. The program has demonstrated dual-target activity with supportive in vitro and in vivo data and is advancing toward drug candidate nomination.
CEO
Greta garrido
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
June 2028
What is your next catalyst (value inflection) update?
Finalize lead candidate selection and initiate IND-enabling studies to advance SBP-001 toward clinical development.
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}